Posted on 12/08/2010 in Pharmaceutical Company Product News Bristol-Myers Squibb has underlined its commitment to combating HIV and Aids by offering renewed support for Aids drug assistance programmes (ADAPs) in the US.
The biopharmaceutical firm has agreed to step up its multi-year support for the ADAP Crisis Task Force's efforts to provide antiretroviral medicines to sufferers of the conditions.
This will involve provision of Bristol-Myers Squibb medication such as Reyataz and Sustiva and builds on an agreement originally signed in March 2010.
In addition, the company conducts a number of its own access to medicines initiatives for Aids patients, including the Access Virology scheme and the Atripla Co-Pay Assistance Program, conducted in association with Gilead Sciences.
Raymond Sacchetti, senior vice-president of virology at Bristol-Myers Squibb, said this commitment is necessary in dealing with a "challenging public health need".
Last month, the company published data from a survey which highlighted the role played by emotional issues in HIV and Aids treatment, with many sufferers feeling too ashamed or fearful to seek medical aid. Other news stories from 12/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
